ReviewSurgery in practice and science2026
Tranexamic acid in radical cystectomy: a systematic review and meta-analysis.
Review in Surgery in practice and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radical cystectomy is associated with substantial blood loss and transfusion requirements, raising the potential role of tranexamic acid (TXA) to mitigate these risks. However, its effectiveness and safety in this context remain to be fully established. Methods: A comprehensive search of PubMed, Embase, Web of Science, and Scopus from inception to May 19, 2025, identified studies involving adult patients undergoing cystectomy (partial or radical) comparing TXA with placebo, no treatment, or alternative hemostatic agents. Results: Four studies (1 RCT, 3 cohort studies) with sample sizes ranging from 64 to 936 patients were included. TXA significantly reduced estimated blood loss (SMD = -0.11; 95% CI: -0.21, -0.01; p = 0.03) and total transfusion volume (SMD = -0.28; 95% CI: -0.54, -0.02; p = 0.04). The odds of receiving any transfusion decreased by 52% (OR = 0.48; 95% CI: 0.30, 0.77; p = 0.002), with postoperative transfusion reduction particularly notable (OR = 0.32; 95% CI: 0.16, 0.63; p < 0.001). TXA showed no significant effect on intraoperative transfusion needs (OR = 0.95; p = 0.79) or perioperative hemoglobin change (SMD = 0.17; p = 0.08). Importantly, TXA did not increase VTE risk (OR = 1.49; p = 0.16) and was associated with a lower postoperative mortality in pooled analyses (OR = 0.62; 95% CI: 0.47, 0.82; p = 0.001). Conclusions: Tranexamic acid appears effective in reducing blood loss and transfusion requirements during cystectomy, with no evidence of increased VTE risk and a potential survival benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.